New hope for hepatitis b patients when standard drugs fail

NCT ID NCT07090759

Recruiting now Disease control Sponsor: Fujian Akeylink Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new oral drug called Neracorvir (GST-HG141) for people with chronic hepatitis B who are still showing signs of the virus despite taking standard antiviral pills. Over 500 participants will be randomly assigned to receive either the new drug or a placebo, in addition to their current medication, to see if it helps lower the virus levels more effectively. The main goal is to see if adding Neracorvir is safe and can get the amount of virus in the blood down to an undetectable level.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shulan(Hangzhou) Hospital
RECRUITING

Hangzhou, Zhejiang, 310011, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC HEPATITIS B